Tag: Policy + Advocacy Updates

In June 2022, World Trade Organization (WTO) member states agreed to waive certain WTO intellectual property protections for COVID-19 vaccines. The U.S. Trade Representative (USTR) has been considerin...

Weekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders  This month CBSA partnered with both Terumo Blood and Cell Technologies (Terumo BCT) and AGC Biologics to host...

Earlier this month, CBSA participated in PASTEUR Advocacy Day, joining Biotechnology Innovation Organization (BIO) and other organizations, including Infectious Diseases Society of America, Cystic Fib...

Elyse Blazevich, President & CEO, Colorado BioScience Association Colorado’s life sciences community and our state leaders share an unwavering commitment to improving patient lives and making sure...

FDA Issues Three Guidances on Premarket Notification [510(k)] Program  On September 7, 2023, the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) issu...

On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to price controls in Medicare under the Inflation Reduction Act...

CBSA advocates for policies that improve patient access to life-saving novel technologies. This week, CBSA signed on to a letter responding to the long-awaited proposed Transitional Coverage for Emerg...

As the Colorado Prescription Drug Affordability Board (PDAB) begins affordability reviews of the five prescription drugs selected earlier this month, it is reaching out to stakeholders to request thei...

On Friday, August 4, the Colorado Prescription Drug Affordability Board (PDAB) selected five drugs for affordability reviews: Enbrel, Genvoya, Cosentyx, Stelara, and Trikafta. PDAB staff plan to begin...

Congress moved forward with its efforts to address drug shortages, drug pricing, pharmacy benefit managers (PBMs), and transparency ahead of the August recess. This policy post covers the discussion d...